Maxime CULOT

Has grant

Associate professor

Université d'Artois

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Maxime Culot is an Associate Professor at the University of Artois in France. His research focuses on areas including chronic kidney disease, toxicity of drugs and chemicals, and the delivery of biologics. He has published numerous articles exploring transporter-mediated interactions, the use of induced pluripotent stem cells, and methods for enhancing oral delivery of therapeutics. His work contributes to advancing the understanding of neurotoxicity and the Blood-Brain Barrier through innovative in vitro models.

Recent Grants

Grant: Close

Gut-To-Blood: a platform for oral systemic delivery of targeted therapies

Open Date: 2020-10-01

Close Date: 2023-09-01

Grant: Close

In3 - An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment

Open Date: 2017-01-01

Close Date: 2021-01-01

Grant: Close

DiaSyn - Development of a new in vivo radiotracer for alpha-synuclein

Open Date: 2016-01-01

Close Date: 2019-01-01

Grant: Close

BtRAIN – European brain Barriers phD training Network

Open Date: 2016-01-01

Close Date: 2019-01-01

Grant: Close

Predict-IV - Profiling the toxicity of new drugs: a non-animal-based approach integrating toxico-dynamics and biokinetics

Open Date: 2013-01-01

Close Date: 2018-01-01

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (9)

Anja Wilmes

University of Amsterdam

NETHERLANDS

View details

V. Chandrasekaran

University of Amsterdam

NETHERLANDS

View details

Emma E.J. Kasteel

Utrecht University

NETHERLANDS

View details

Fabien Gosselet

Professeurs des Universités

Université d'Artois

FRANCE

View details

Leonardo Scapozza

Full Professor

University of Geneva

SWITZERLAND

View details

Magali Zeisser Labouebe

University of Geneva

SWITZERLAND

View details

Paul Jennings

University of Amsterdam

NETHERLANDS

View details

Irena Loryan

Associate Professor, PI, Researcher

Uppsala University

SWEDEN

View details

Yogeshvar Kalia

Full Professor (Medicinal/Pharmaceutical Chemistry)

University of Geneva

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Maxime CULOT

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Transporter-Mediated Interactions Between Uremic Toxins and Drugs: A Hidden Driver of Toxicity in Chronic Kidney Disease

Cyclosporin A toxicity on endothelial cells differentiated from induced pluripotent stem cells: Assembling an adverse outcome pathway

Minimum information for studies of extracellular vesicles (MISEV) as toolbox for rigorous, reproducible and homogeneous studies on extracellular vesicles

Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model

Evaluation of the impact of iPSC differentiation protocols on transcriptomic signatures

Differential Blood–Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro

Challenges and Opportunities in the Oral Delivery of Recombinant Biologics

Predicting human neurotoxicity of propylene glycol methyl ether (PGME) by implementing in vitro neurotoxicity results into toxicokinetic modelling

An in vitro strategy using multiple human induced pluripotent stem cell-derived models to assess the toxicity of chemicals

Challenges and opportunities in the use of transcriptomics characterization for human iPSC-derived BBB models

Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound

Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier

Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure–Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor

Central nervous system delivery of molecules across the blood-brain barrier

Application of in vitro data in physiologically-based kinetic models for quantitative in vitro-in vivo extrapolation: A case-study for baclofen

Flow induces barrier and glycocalyx-related genes and negative surface charge in a lab-on-a-chip human blood-brain barrier model

Transport Studies Using Blood-Brain Barrier In Vitro Models: A Critical Review and Guidelines.

Collaborators (9)

Anja Wilmes

V. Chandrasekaran

Emma E.J. Kasteel

Fabien Gosselet

Leonardo Scapozza

Magali Zeisser Labouebe

Paul Jennings

Irena Loryan

Yogeshvar Kalia

Make your next move.